Transcatheter aortic valve implantation: a new standard of care

Adam J Nelson, Nicholas J Montarello, Claudia S Cosgrove, Ross L Roberts-Thomson, Sinny Delacroix, Ramesh G Chokka, Joseph K Montarello and Stephen G Worthley
Med J Aust 2018; 209 (3): . || doi: 10.5694/mja17.01255
Published online: 6 August 2018



  • Aortic stenosis is the most common valvular lesion requiring intervention and with an ageing population, its burden is likely to increase.
  • Increasing comorbidity and a desire for less invasive treatment strategies has facilitated the expansion of percutaneous aortic valve therapies.
  • Robust clinical trial data are now available to support the role of transcatheter aortic valve implantation (TAVI) in patients of prohibitive, high and now intermediate surgical risk.
  • The introduction of a Medicare Benefits Schedule reimbursement is likely to see TAVI use grow exponentially in Australia over the next 5 years.
  • Clinical trials evaluating low risk patients may be the final frontier to see TAVI become the standard of care for most patients with severe aortic stenosis.


  • Adam J Nelson
  • Nicholas J Montarello
  • Claudia S Cosgrove
  • Ross L Roberts-Thomson
  • Sinny Delacroix
  • Ramesh G Chokka
  • Joseph K Montarello
  • Stephen G Worthley

  • Royal Adelaide Hospital, Adelaide, SA


Competing interests:

Stephen Worthley consults for and has received honoraria from Medtronic and Abbott.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.